Get started
BioMarin Pharmaceutical Inc.BioMarin Pharmaceutical Inc.BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options Bonds

BMRN chart


Full chart

BMRN upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪11.44 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
25.83
Basic EPS (TTM)
2.25 USD
Net income (FY)
‪426.86 M‬ USD
Revenue (FY)
‪2.84 B‬ USD
Shares float
‪189.25 M‬
Beta (1Y)
0.45

Employees


Employees (FY)
‪3.04 K‬
Change (1Y)
−361 −10.61%
Revenue / Employee (1Y)
‪933.95 K‬ USD
Net income / Employee (1Y)
‪140.41 K‬ USD

About BioMarin Pharmaceutical Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Alexander Hardy
Website
biomarin.com
Headquarters
San Rafael
Founded
1997
FIGI
BBG000CZWZ05
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

BMRN news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

BMRN highest yielding bonds


BMRN5187965
BioMarin Pharmaceutical Inc. 1.25% 15-MAY-2027
Yield to maturity
5.36%
Maturity date
May 15, 2027

See all BMRN bonds 

Sparks


Curated watchlists where BMRN is featured.

See all sparks 


Check out other big names from the same industry as BMRN.

Frequently Asked Questions


The current price of BMRN is 60.02 USD — it has increased by 1.17% in the past 24 hours. Watch BioMarin Pharmaceutical Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange BioMarin Pharmaceutical Inc. stocks are traded under the ticker BMRN.
BMRN stock has fallen by −0.21% compared to the previous week, the month change is a −14.26% fall, over the last year BioMarin Pharmaceutical Inc. has showed a −35.17% decrease.
We've gathered analysts' opinions on BioMarin Pharmaceutical Inc. future price: according to them, BMRN price has a max estimate of 126.00 USD and a min estimate of 65.00 USD. Watch BMRN chart and read a more detailed BioMarin Pharmaceutical Inc. stock forecast: see what analysts think of BioMarin Pharmaceutical Inc. and suggest that you do with its stocks.
BMRN reached its all-time high on Jul 20, 2015 with the price of 151.75 USD, and its all-time low was 3.57 USD and was reached on Sep 4, 2002. View more price dynamics on BMRN chart.
See other stocks reaching their highest and lowest prices.
BMRN stock is 2.20% volatile and has beta coefficient of 0.45. Track BioMarin Pharmaceutical Inc. stock price on the chart and check out the list of the most volatile stocks — is BioMarin Pharmaceutical Inc. there?
Today BioMarin Pharmaceutical Inc. has the market capitalization of ‪11.44 B‬, it has decreased by −12.92% over the last week.
Yes, you can track BioMarin Pharmaceutical Inc. financials in yearly and quarterly reports right on TradingView.
BioMarin Pharmaceutical Inc. is going to release the next earnings report on Apr 23, 2025. Keep track of upcoming events with our Earnings Calendar.
BMRN earnings for the last quarter are 0.64 USD per share, whereas the estimation was 0.53 USD resulting in a 19.84% surprise. The estimated earnings for the next quarter are 0.69 USD per share. See more details about BioMarin Pharmaceutical Inc. earnings.
BioMarin Pharmaceutical Inc. revenue for the last quarter amounts to ‪747.00 M‬ USD, despite the estimated figure of ‪712.30 M‬ USD. In the next quarter, revenue is expected to reach ‪740.10 M‬ USD.
BMRN net income for the last quarter is ‪124.94 M‬ USD, while the quarter before that showed ‪106.08 M‬ USD of net income which accounts for 17.78% change. Track more BioMarin Pharmaceutical Inc. financial stats to get the full picture.
No, BMRN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 15, 2025, the company has ‪3.04 K‬ employees. See our rating of the largest employees — is BioMarin Pharmaceutical Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BioMarin Pharmaceutical Inc. EBITDA is ‪571.64 M‬ USD, and current EBITDA margin is 22.06%. See more stats in BioMarin Pharmaceutical Inc. financial statements.
Like other stocks, BMRN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BioMarin Pharmaceutical Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BioMarin Pharmaceutical Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BioMarin Pharmaceutical Inc. stock shows the strong sell signal. See more of BioMarin Pharmaceutical Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.